• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Erythropoietin-stimulating agents may not improve quality of life for patients with chronic kidney disease

byJeffrey CampbellandSai Folmsbee
February 16, 2016
in Chronic Disease, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. From this systematic review and meta-analysis, use of erythropoietin-stimulating agents (ESAs) to achieve high hemoglobin targets in patients with chronic kidney disease (CKD) did not significantly improve health-related quality of life (HRQOL) compared to using ESAs to achieve lower hemoglobin targets.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Erythropoietin-stimulating agents (ESAs), a class of drugs that boost hemoglobin levels, are frequently used to combat anemia in patients with chronic kidney disease (CKD). Despite the potentially severe side effects of using ESAs, physicians often prescribe them to help patients achieve “high” hemoglobin targets, with the notion that higher hemoglobin levels may improve quality of life. Therefore, this study aimed to test whether achieving higher hemoglobin levels would improve health-related quality of life (HRQOL). The study combined results from prior trials of ESAs used to treat anemia in patients with CKD and compared improvement in HRQOL among trial participants who were randomized to either higher or lower hemoglobin targets. Overall, trial participants who were randomized to higher targets showed no clinically significant improvements in HRQOL compared to trial participants randomized to lower targets. This result was also consistent among key subgroups, such as participants on dialysis. Importantly, the trials included in this study varied in terms of what hemoglobin targets were considered “high” and “low”, as well as in which ESAs were used and the duration of follow-up, potentially limiting these findings. Nevertheless, these results suggest that using higher hemoglobin targets to guide ESA therapy among patients with CKD likely results in no clinically significant benefit to HRQOL.

Click to read the study published today in the Annals of Internal Medicine

Relevant Reading: Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis

In-Depth [systematic review and meta-analysis]: This study combined results from 17 randomized, controlled trials of ESAs to treat anemia in participants with CKD. All trials used two hemoglobin targets, a “low” (or placebo) target, which ranged from 7.4–12 g/L, and a “high” target, which ranged from 10.2–13.6 g/L. Included trials used two measures of HRQOL, the Short-Form Health Survey (SF-36), and the Kidney Dialysis Questionnaire (KDQ), and measured HRQOL at least twice during the trial. Overall, there was no clinically significant improvement in HRQOL in participants randomized to high hemoglobin targets compared to participants randomized to low targets. In subgroup analysis, physical function improved among non-dialysis CKD participants randomized to achieve higher hemoglobin targets (SF-36 difference 3.61, 95%CI 6.54 to 0.67), but this improvement was not clinically meaningful.

Image: CC/Wiki

RELATED REPORTS

Uric acid-lowering therapy not associated with improved kidney function

Risk of chronic kidney disease progression may be greater amongst patients with obstructive sleep apnea

Wellness Check: Sleep

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic kidney diseaseerythropoeisis-stimulating agents (ESAs)
Previous Post

Obesity in critically ill children associated with increased mortality

Next Post

Certain financial incentive programs may promote increased physical activity

RelatedReports

Being overweight and obese associated with increased incidence of chronic kidney disease
Chronic Disease

Uric acid-lowering therapy not associated with improved kidney function

June 13, 2022
CPAP may not decrease cardiovascular events in sleep apnea
Nephrology

Risk of chronic kidney disease progression may be greater amongst patients with obstructive sleep apnea

March 14, 2022
Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

March 10, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Infectious Disease

Post-COVID Syndrome is linked to higher mortality risk and multi-organ dysfunction

April 14, 2021
Next Post
Certain financial incentive programs may promote increased physical activity

Certain financial incentive programs may promote increased physical activity

Unpaid caregivers of older adults experience emotional, physical, and financial difficulty

Unpaid caregivers of older adults experience emotional, physical, and financial difficulty

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

2 Minute Medicine Rewind February 15, 2016

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.